Why the study?
Do nonvitamin-K antagonist oral anticoagulants prevent stroke compared to vitamin-K antagonists in patients with atrial fibrillation in a real-world setting?
Do nonvitamin-K antagonist oral anticoagulants prevent stroke compared to vitamin-K antagonists in patients with atrial fibrillation in a real-world setting?
Real-world data confirms the efficacy of NOACs (dabigatran, rivaroxaban, apixaban) versus VKAs for stroke prevention in atrial fibrillation.
Supports NOAC preference over VKAs for AF stroke prevention; confirms RCT findings in real-world populations.
This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity.
No takes yet. Share an insight, caveat, or question.
Ntaios et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: